
Sean Mcgarry
Examiner (ID: 6820, Phone: (571)272-0761 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1635, 1674, 1621, 1809, 1624, 1805 |
| Total Applications | 1927 |
| Issued Applications | 1068 |
| Pending Applications | 344 |
| Abandoned Applications | 554 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19984286
[patent_doc_number] => 20250122508
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-17
[patent_title] => Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell
[patent_app_type] => utility
[patent_app_number] => 18/982078
[patent_app_country] => US
[patent_app_date] => 2024-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17589
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 274
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18982078
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/982078 | Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell | Dec 15, 2024 | Pending |
Array
(
[id] => 19631442
[patent_doc_number] => 20240409891
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-12
[patent_title] => MODELS OF TAUOPATHY
[patent_app_type] => utility
[patent_app_number] => 18/819435
[patent_app_country] => US
[patent_app_date] => 2024-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45554
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 279
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18819435
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/819435 | Models of tauopathy | Aug 28, 2024 | Issued |
Array
(
[id] => 19615374
[patent_doc_number] => 20240401054
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/158290
[patent_app_country] => US
[patent_app_date] => 2024-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 114234
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158290
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/158290 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | Aug 25, 2024 | Pending |
Array
(
[id] => 19658787
[patent_doc_number] => 20240425852
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
[patent_app_type] => utility
[patent_app_number] => 18/774194
[patent_app_country] => US
[patent_app_date] => 2024-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25077
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18774194
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/774194 | Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same | Jul 15, 2024 | Pending |
Array
(
[id] => 19684432
[patent_doc_number] => 20250002977
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-02
[patent_title] => SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATION
[patent_app_type] => utility
[patent_app_number] => 18/765750
[patent_app_country] => US
[patent_app_date] => 2024-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18746
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 340
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18765750
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/765750 | Sample splitting for multiplexed detection of nucleic acids without amplification | Jul 7, 2024 | Issued |
Array
(
[id] => 19631491
[patent_doc_number] => 20240409940
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-12
[patent_title] => MODIFIED AAV CONSTRUCTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/746105
[patent_app_country] => US
[patent_app_date] => 2024-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23676
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18746105
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/746105 | MODIFIED AAV CONSTRUCTS AND USES THEREOF | Jun 17, 2024 | Pending |
Array
(
[id] => 19746005
[patent_doc_number] => 20250034570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/738165
[patent_app_country] => US
[patent_app_date] => 2024-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56463
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18738165
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/738165 | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Jun 9, 2024 | Pending |
Array
(
[id] => 20272233
[patent_doc_number] => 12442003
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-14
[patent_title] => Trans-splicing molecules
[patent_app_type] => utility
[patent_app_number] => 18/673713
[patent_app_country] => US
[patent_app_date] => 2024-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 33
[patent_no_of_words] => 27885
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18673713
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/673713 | Trans-splicing molecules | May 23, 2024 | Issued |
Array
(
[id] => 19556805
[patent_doc_number] => 20240368597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => Antisense Nucleic Acids
[patent_app_type] => utility
[patent_app_number] => 18/662046
[patent_app_country] => US
[patent_app_date] => 2024-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14657
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18662046
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/662046 | Antisense Nucleic Acids | May 12, 2024 | Abandoned |
Array
(
[id] => 19643201
[patent_doc_number] => 20240417721
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES
[patent_app_type] => utility
[patent_app_number] => 18/655096
[patent_app_country] => US
[patent_app_date] => 2024-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20287
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18655096
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/655096 | SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | May 2, 2024 | Pending |
Array
(
[id] => 19601410
[patent_doc_number] => 20240392290
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => STAUFEN1 REGULATING AGENTS AND ASSOCIATED METHODS
[patent_app_type] => utility
[patent_app_number] => 18/623472
[patent_app_country] => US
[patent_app_date] => 2024-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36656
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18623472
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/623472 | STAUFEN1 REGULATING AGENTS AND ASSOCIATED METHODS | Mar 31, 2024 | Pending |
Array
(
[id] => 19449251
[patent_doc_number] => 20240309381
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/608561
[patent_app_country] => US
[patent_app_date] => 2024-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38661
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18608561
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/608561 | METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY | Mar 17, 2024 | Pending |
Array
(
[id] => 19724330
[patent_doc_number] => 20250027081
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-23
[patent_title] => METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/599942
[patent_app_country] => US
[patent_app_date] => 2024-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17525
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18599942
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/599942 | METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION | Mar 7, 2024 | Pending |
Array
(
[id] => 19318659
[patent_doc_number] => 20240240202
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERY
[patent_app_type] => utility
[patent_app_number] => 18/441280
[patent_app_country] => US
[patent_app_date] => 2024-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36218
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -77
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441280
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/441280 | Compositions and therapeutic methods of microRNA gene delivery | Feb 13, 2024 | Issued |
Array
(
[id] => 19234045
[patent_doc_number] => 20240191237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell
[patent_app_type] => utility
[patent_app_number] => 18/407780
[patent_app_country] => US
[patent_app_date] => 2024-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23030
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 256
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18407780
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/407780 | Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell | Jan 8, 2024 | Issued |
Array
(
[id] => 19226868
[patent_doc_number] => 12006502
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-11
[patent_title] => Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
[patent_app_type] => utility
[patent_app_number] => 18/407815
[patent_app_country] => US
[patent_app_date] => 2024-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 13
[patent_no_of_words] => 23029
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 348
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18407815
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/407815 | Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell | Jan 8, 2024 | Issued |
Array
(
[id] => 19368528
[patent_doc_number] => 12060602
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-13
[patent_title] => Sample splitting for multiplexed detection of nucleic acids without amplification
[patent_app_type] => utility
[patent_app_number] => 18/406159
[patent_app_country] => US
[patent_app_date] => 2024-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 18707
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 165
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18406159
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/406159 | Sample splitting for multiplexed detection of nucleic acids without amplification | Jan 6, 2024 | Issued |
Array
(
[id] => 19249092
[patent_doc_number] => 20240200079
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) Inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/392181
[patent_app_country] => US
[patent_app_date] => 2023-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20434
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18392181
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/392181 | Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors | Dec 20, 2023 | Issued |
Array
(
[id] => 20108496
[patent_doc_number] => 12359205
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-15
[patent_title] => Aptamers for personal health care applications
[patent_app_type] => utility
[patent_app_number] => 18/512207
[patent_app_country] => US
[patent_app_date] => 2023-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 30
[patent_no_of_words] => 19302
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18512207
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/512207 | Aptamers for personal health care applications | Nov 16, 2023 | Issued |
Array
(
[id] => 19157735
[patent_doc_number] => 20240150442
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => DNA Monoclonal Antibodies Targeting Influenza Virus
[patent_app_type] => utility
[patent_app_number] => 18/511108
[patent_app_country] => US
[patent_app_date] => 2023-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24063
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18511108
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/511108 | DNA Monoclonal Antibodies Targeting Influenza Virus | Nov 15, 2023 | Abandoned |